- Home
- NRT vs CGTX Comparison
NRT vs CGTX Comparison
Compare NRT & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRT | CGTX |
|---|---|---|
| Founded | 1975 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.3M | 94.5M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NRT | CGTX |
|---|---|---|
| Price | $8.75 | $1.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 107.5K | ★ 573.4K |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | ★ 9.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $40.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.00 | $0.22 |
| 52 Week High | $10.49 | $3.83 |
Technical Indicators
Market Signals| Indicator | NRT | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.89 | 51.98 |
| Support Level | $8.50 | $1.00 |
| Resistance Level | $9.46 | $1.19 |
| Average True Range (ATR) | 0.58 | 0.07 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 31.45 | 75.00 |
Price Performance
Historical ComparisonAbout NRT North European Oil Royality Trust
North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.